Eli Lilly Valuation
| LLY Stock | 38.40 1.40 3.78% |
At this time, the firm appears to be fairly valued. Eli Lilly CDR shows a prevailing Real Value of USD38.21 per share. The current price of the firm is USD38.4. Our model computes the value of Eli Lilly CDR from reviewing the firm fundamentals such as Market Capitalization of 1.02 T, number of employees of 9, and Price To Book of 38.95 X as well as analyzing its technical indicators and probability of bankruptcy.
Price Book 38.9493 | Enterprise Value 1.4 T | Enterprise Value Ebitda 39.1969 | Price Sales 15.6925 | Forward PE 32.4675 |
Fairly Valued
Today
Please note that Eli Lilly's price fluctuation is very steady at this time. Calculation of the real value of Eli Lilly CDR is based on 3 months time horizon. Increasing Eli Lilly's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Eli Lilly is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Eli Stock. However, Eli Lilly's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 38.4 | Real 38.21 | Hype 38.4 |
The intrinsic value of Eli Lilly's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Eli Lilly's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Eli Lilly CDR helps investors to forecast how Eli stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Eli Lilly more accurately as focusing exclusively on Eli Lilly's fundamentals will not take into account other important factors: About Eli Lilly Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Eli Lilly CDR. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Eli Lilly CDR based exclusively on its fundamental and basic technical indicators. By analyzing Eli Lilly's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Eli Lilly's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Eli Lilly. We calculate exposure to Eli Lilly's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Eli Lilly's related companies.Other Information on Investing in Eli Stock
Eli Lilly financial ratios help investors to determine whether Eli Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Eli with respect to the benefits of owning Eli Lilly security.